Squarepoint’s Disc Medicine IRON Stock Holding History

Squarepoint’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,000	Closed	-$951K	–	4997
2024 Q4	$951K	Buy	+15,000	New	+$868K	﹤0.01%	3116

Other funds holding IRON

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Squarepoint's IRON Position: Q2 2026 in Review

Squarepoint increased its Disc Medicine (IRON) stake by 139% in Q2 2026, buying an estimated $3.03M and bringing the position to 75,872 shares worth $5.55M. The position accounts for 0.01% of the portfolio, ranked #1526.

Squarepoint first reported a position in IRON in Q4 2021 and has held it in 8 quarters since. 217 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

Squarepoint held 75,872 shares of Disc Medicine worth $5.55M as of Q2 2026.
Squarepoint bought 44,163 Disc Medicine shares in Q2 2026, an estimated $3.03M.
Disc Medicine made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1526 holding.
Squarepoint first reported a position in Disc Medicine in Q4 2021 and has held it in 8 quarters since.
217 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.